187 related articles for article (PubMed ID: 29792808)
1. Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.
Petersburg JR; Shen J; Csizmar CM; Murphy KA; Spanier J; Gabrielse K; Griffith TS; Fife B; Wagner CR
ACS Nano; 2018 Jul; 12(7):6563-6576. PubMed ID: 29792808
[TBL] [Abstract][Full Text] [Related]
2. Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings.
Petersburg J; Vallera DA; Wagner CR
Mol Cancer Ther; 2023 Mar; 22(3):371-380. PubMed ID: 36548194
[TBL] [Abstract][Full Text] [Related]
3. Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.
Mews EA; Beckmann P; Patchava M; Wang Y; Largaespada DA; Wagner CR
ACS Nano; 2022 Aug; 16(8):12185-12201. PubMed ID: 35876221
[TBL] [Abstract][Full Text] [Related]
4. Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
Karches CH; Benmebarek MR; Schmidbauer ML; Kurzay M; Klaus R; Geiger M; Rataj F; Cadilha BL; Lesch S; Heise C; Murr R; Vom Berg J; Jastroch M; Lamp D; Ding J; Duewell P; Niederfellner G; Sustmann C; Endres S; Klein C; Kobold S
Clin Cancer Res; 2019 Oct; 25(19):5890-5900. PubMed ID: 31285373
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression.
Kilic O; Matos de Souza MR; Almotlak AA; Wang Y; Siegfried JM; Distefano MD; Wagner CR
J Med Chem; 2020 Sep; 63(18):10235-10245. PubMed ID: 32852209
[TBL] [Abstract][Full Text] [Related]
6. Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.
Li Q; So CR; Fegan A; Cody V; Sarikaya M; Vallera DA; Wagner CR
J Am Chem Soc; 2010 Dec; 132(48):17247-57. PubMed ID: 21077608
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
Hong R; Zhou Y; Tian X; Wang L; Wu X
Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
[TBL] [Abstract][Full Text] [Related]
8. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
[TBL] [Abstract][Full Text] [Related]
9. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
10. The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
Suurs FV; Lorenczewski G; Stienen S; Friedrich M; de Vries EGE; de Groot DJA; Lub-de Hooge MN
J Nucl Med; 2020 Nov; 61(11):1594-1601. PubMed ID: 32284393
[TBL] [Abstract][Full Text] [Related]
11. Engineering Reversible Cell-Cell Interactions with Lipid Anchored Prosthetic Receptors.
Csizmar CM; Petersburg JR; Hendricks A; Stern LA; Hackel BJ; Wagner CR
Bioconjug Chem; 2018 Apr; 29(4):1291-1301. PubMed ID: 29537253
[TBL] [Abstract][Full Text] [Related]
12. The combination therapy with EpCAM/CD3 BsAb and MUC-1/CD3 BsAb elicited antitumor immunity by T-cell adoptive immunotherapy in lung cancer.
Wang C; Chen S; Wu Y; Wu D; Wang J; Li F
Int J Med Sci; 2021; 18(15):3380-3388. PubMed ID: 34522164
[TBL] [Abstract][Full Text] [Related]
13. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.
Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S
Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.
Ang WX; Li Z; Chi Z; Du SH; Chen C; Tay JC; Toh HC; Connolly JE; Xu XH; Wang S
Oncotarget; 2017 Feb; 8(8):13545-13559. PubMed ID: 28088790
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a Novel Bispecific Antibody That Activates T Cells
Chornoguz O; Leettola CN; Leander K; Brosnan K; Emmell E; Chiu ML; Santulli-Marotto S
Monoclon Antib Immunodiagn Immunother; 2019 Dec; 38(6):242-254. PubMed ID: 31825302
[TBL] [Abstract][Full Text] [Related]
16. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
[TBL] [Abstract][Full Text] [Related]
17. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
18. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.
Terracina KP; Graham LJ; Payne KK; Manjili MH; Baek A; Damle SR; Bear HD
Cancer Immunol Immunother; 2016 Sep; 65(9):1061-73. PubMed ID: 27416831
[TBL] [Abstract][Full Text] [Related]
19. Prosthetic Antigen Receptors.
Shen J; Vallera DA; Wagner CR
J Am Chem Soc; 2015 Aug; 137(32):10108-11. PubMed ID: 26230248
[TBL] [Abstract][Full Text] [Related]
20. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
